NasdaqGS:NTRABiotechs
Did Strong New Signatera ctDNA Data Just Shift Natera’s (NTRA) Investment Narrative?
Natera recently reported that the phase III CALGB (Alliance)/SWOG 80702 trial, now published in JAMA Oncology, showed that adding celecoxib to FOLFOX chemotherapy after surgery reduced recurrence and death risk in Signatera-positive stage III colorectal cancer patients, while multiple new breast cancer studies further reinforced the prognostic power of its Signatera ctDNA assays.
Together with a fresh MiRaDoR collaboration in hormone receptor-positive breast cancer and updated PALLAS MRD...